Premium
Re‐evaluation of the pharmacokinetics of xylazine administered to Thoroughbred horses
Author(s) -
HabershonButcher Jocelyn,
Cutler Charlotte,
Viljanto Marjaana,
Hincks Pamela R.,
Biddle Simon,
Paine Stuart W.
Publication year - 2020
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12820
Subject(s) - xylazine , pharmacokinetics , urine , metabolite , medicine , veterinary drugs , sedative , pharmacology , plasma concentration , active metabolite , anesthesia , veterinary medicine , ketamine
Abstract Xylazine is widely used worldwide as a short‐acting sedative in general equine and racing practice. In the UK, although it has a legitimate use during training, equine anti‐doping rules state it is a prohibited substance on race day. The aim of the study was to produce a detection time (DT) to better inform European veterinary surgeons so that xylazine can be used appropriately under regulatory rules. Previous publications have various limitations pertaining to analysis method, particularly for plasma and limited length of time of sample collection. In this study, pharmacokinetic data were produced for xylazine and 4‐OH‐xylazine in equine urine and plasma following a single intravenous xylazine dose of 0.4 mg/kg to six Thoroughbred horses. Pharmacokinetic parameters were generated from a 3‐compartmental model with clearance = 15.8 ± 4.88 ml min ‐1 kg ‐1 , Vss = 1.44 ± 0.38 L/kg, terminal half‐life = 29.8 ± 12.7 hr and a DT determined at 71 hr for the administration of xylazine (Chanazine ® ) in plasma and urine. Urine screening should aim to detect the 4‐OH‐xylazine metabolite, which can act as an indicator for the xylazine plasma concentration. A DT of 72 hr has been agreed by the European Horserace Scientific Liaison Committee, to be implemented in June 2019.